决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Case Report: Hemophagocytic lymphohistiocytosis after SARS-CoV-2 infection revealing clinically diagnosed stage IVB diffuse large B-cell lymphoma in quiescent adult-onset Still's disease.
轻度 SARS-CoV-2 感染可能作为共触发因素或暴露事件,而非 HLH 的唯一病因。持续高乳酸脱氢酶和可溶性白细胞介素-2 受体、弥漫性淋巴结肿大、克隆性成熟 B 细胞、淋巴瘤相关突变以及广泛病原体检测阴性,应促使评估隐匿性淋巴瘤相关 HLH。
成人噬血细胞性淋巴组织细胞增生症(HLH)可能由感染、恶性肿瘤或系统性炎症性疾病触发。当近期SARS-CoV-2感染、静止期成人起病Still病(AOSD)和隐匿性B细胞克隆性疾病共存时,病因归属具有挑战性。病例报告:一名71岁男性,AOSD已用低剂量甲氨蝶呤控制14年,在轻度SARS-CoV-2感染后出现持续发热和乏力。随后他出现血细胞减少、高铁蛋白血症、乳酸脱氢酶显著升高、弥漫性FDG高摄取淋巴结肿大、肝脾肿大、可溶性白细胞介素-2受体升高、NK 细胞活性降低以及骨髓噬血现象,符合HLH标准。广泛的病原体评估,包括血液和骨髓宏基因组下一代测序,未发现其他感染性触发因素。骨髓组织病理学未显示明确的肿瘤细胞;然而,流式细胞术检测到单克隆成熟B细胞,外周血涂片高通量测序检测到淋巴瘤相关突变,包括MYD88、CD79B、IGLL5、PRDM1、DTX1、DUSP2和BTG1。多学科会诊倾向于可能为淋巴瘤相关HLH,临床诊断为IVB期弥漫性大B细胞淋巴瘤。针对HLH的治疗继以基于利妥昔单抗的淋巴瘤导向化疗带来了短暂的临床改善,但患者后来死于感染性并发症。
BACKGROUND: Adult hemophagocytic lymphohistiocytosis (HLH) may be triggered by infection, malignancy, or systemic inflammatory disease. Attribution is challenging when recent SARS-CoV-2 infection, quiescent adult-onset Still's disease (AOSD), and an occult B-cell clonal disorder coexist. CASE REPORT: A 71-year-old man with AOSD controlled for 14 years on low-dose methotrexate developed persistent fever and fatigue after mild SARS-CoV-2 infection. He subsequently developed cytopenias, hyperferritinemia, markedly elevated lactate dehydrogenase, diffuse FDG-avid lymphadenopathy, hepatosplenomegaly, elevated soluble interleukin-2 receptor, reduced natural killer-cell activity, and bone marrow hemophagocytosis, fulfilling HLH criteria. Broad pathogen evaluation, including blood and bone marrow metagenomic next-generation sequencing, did not identify an alternative infectious trigger. Bone marrow histopathology did not show definite tumor cells; however, flow cytometry identified monoclonal mature B cells, and peripheral-blood smear high-throughput sequencing detected lymphoma-associated mutations including MYD88, CD79B, IGLL5, PRDM1, DTX1, DUSP2, and BTG1. Multidisciplinary consultation favored probable lymphoma-associated HLH with clinically diagnosed stage IVB diffuse large B-cell lymphoma. HLH-directed therapy followed by rituximab-based lymphoma-directed chemotherapy led to transient clinical improvement, but the patient later died from infectious complications. CONCLUSION: Mild SARS-CoV-2 infection may act as a co-trigger or unmasking event rather than the sole cause of HLH. Persistent high lactate dehydrogenase and soluble interleukin-2 receptor, diffuse lymphadenopathy, clonal mature B cells, lymphoma-associated mutations, and negative broad pathogen testing should prompt evaluation for occult lymphoma-associated HLH.
MEMBER ACCOUNT
登录成功会直接打开下一页。